Pfizer Reports Data from P-III (TALAPRO-2) Trial of Talzenna + Xtandi for Metastatic Castration Resistant Prostate Cancer (mCRPC)
Shots:
- The P-III (TALAPRO-2) trial assessed Talzenna + Xtandi vs PBO + Xtandi in mCRPC ± HRRm pts for >4yr. (mFU: 52.5mos.) that were randomized into 2 Arms (A1: no genetic selection & A2: HRRm pts)
- A1 showed reduced death risk by 20% & mOS of 45.8 vs 37mos. while A2 depicted death risk reduction by 38% & mOS of 45.1 vs 31.1mos.; benefit was seen in both BRCA & non-BRCA gene alterations
- Also, Final analysis confirmed sustained clinical benefits in both arms, with updated rPFS & 2EPs aligning with primary analyses previously published in The Lancet & Nature Medicine. Data to be presented in ASCO GU (Abstract- A1: LBA18 & A2: LBA141) & is shared with the US FDA, EMA & other authorities
Ref: Pfizer | Image: Pfizer
Related News:- Pfizer Reports the US FDA Approval of Adcetris Regimen to Treat R/R Diffuse Large B-Cell Lymphoma (DLBCL)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
